GlassScriptPhysician profile
Michael Luz Avaricio
NPI 1639275084
$40,907.21
in general payments reported to CMS, 2019-2025
46 companies · $1,525 in 2025
The $1,525 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $11K · 2021: $2,475 · 2022: $2,636 · 2023: $5,250 · 2024: $2,590 · 2025: $1,525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,544 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,520 · Travel and Lodging: $206 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,543.96 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,520.00 |
| Travel and Lodging | $206.26 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $15,650.49 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $6,982.57 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $3,840.79 | 2019-2025 | Verquvo, Capvaxive |
| Janssen Pharmaceuticals, INC | $2,822.31 | 2019-2024 | Xarelto, Abiraterone Acetate |
| Astrazeneca Pharmaceuticals LP | $2,160.58 | 2019-2025 | Farxiga, Lokelma, Airsupra |
| Boston Scientific Corporation | $1,067.71 | 2019-2024 | |
| Medtronic, INC. | $921.42 | 2022-2023 | Avalus, Cg Future |
| Bayer Healthcare Pharmaceuticals INC. | $916.83 | 2022-2025 | |
| Actelion Pharmaceuticals US, INC. | $888.65 | 2019-2025 | Opsumit, Uptravi |
| E.R. Squibb & Sons, L.L.C. | $681.60 | 2019-2025 | Camzyos, Eliquis |
| Alnylam Pharmaceuticals INC. | $560.78 | 2022-2025 | Amvuttra |
| Novartis Pharmaceuticals Corporation | $530.66 | 2019-2025 | |
| Pfizer INC. | $391.51 | 2019-2021 | |
| Esperion Therapeutics, INC. | $383.74 | 2020-2025 | Nexletol |
| Sanofi-Aventis U.S. LLC | $292.33 | 2019-2022 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Avaricio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.